TOP TEN perturbations for 1555309_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1555309_a_at
Selected probe(set): 232608_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1555309_a_at (232608_x_at) across 6622 perturbations tested by GENEVESTIGATOR:

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):2.79138
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

Barrett's esophagus study 3 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-2.010849
Number of Samples:17 / 18
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

galectin-1 study 1 / vehicle (DTT/polym. B) treated monocyte sample

Relative Expression (log2-ratio):-1.9794302
Number of Samples:3 / 3
Experimental galectin-1 study 1
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, galectin-1 (20 μM) in the presence of 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.
Control vehicle (DTT/polym. B) treated monocyte sample
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 μg/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.

Merkel cell carcinoma study 3 (primary) / skin squamous cell carcinoma study 6

Relative Expression (log2-ratio):-1.8288641
Number of Samples:19 / 4
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).

human AB serum study 1 (late) / IL-4; GM-CSF study 1 (late)

Relative Expression (log2-ratio):1.8143444
Number of Samples:3 / 6
Experimental human AB serum study 1 (late)
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.

skin squamous cell carcinoma study 6 / basal cell carcinoma study 2

Relative Expression (log2-ratio):1.7984991
Number of Samples:4 / 2
Experimental skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-1.7145576
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

esophageal adenocarcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-1.6802855
Number of Samples:20 / 18
Experimental esophageal adenocarcinoma study 1
Esophageal adenocarcinoma (EAC) samples of affected epithelium recovered by laser capture microdissection technique.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):1.6066866
Number of Samples:3 / 8
Experimental esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).
Control esophagus cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the oesophagus (subcutaneously implanted).

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):-1.5973339
Number of Samples:4 / 2
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).